Phase 2Data readout

PRX-115

Chronic refractory gout

PLXProtalix Biotherapeutics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: PRX-115
Development stage: Phase 2
Event type: Data readout
Indication: Chronic refractory gout

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for PRX-115 in Chronic refractory gout. The expected timing is based on the latest available company guidance and may change.

Development notes

11/6/23- Enrollment ongoing. 11/18/24- Presented data via poster ACR Convergence'24. 8/14/25- Initiate trial in H2 2025 and enrollment of first patient in Q4 2025. 11/13/25:- IND for Ph2 in uncontrolled gout was submitted in October 2025 and became effective; Ph2 initiation remains planned for later in 2025. 03/18/26:- RELEASE Ph2 trial actively enrolling with first patients randomized; topline results expected in H2 2027. 05/13/26:- RELEASE Ph2 enrollment continues; company reiterates top-line results anticipated in H2 2027. 08/12/26:- RELEASE Ph2 enrollment continues. Topline results are expected in H2 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source